CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
HBV | Webcasts Back
Webcasts
 
  Release Date 06/14/2010
Expiration Date 06/14/2011
This program has expired. CME credit is no longer available.
     
  Calvin  
     
  Eugene R. Schiff, MD  
  Professor of Medicine
Chief, Division of Hepatology
Director, Center for Liver Diseases
University of Miami School of Medicine
Miami, Florida
 
  View Webcast  
     
  Line  
  Purdue  
  Jointly sponsored by Purdue University College of Pharmacy and the Chronic Liver Disease Foundation.  
     
  This activity supported by:  
  Bristol-Myers Squibb.  
     
 
Target Audience
This activity has been designed to meet the educational needs of healthcare practitioners involved in the care of patients with HBV.
 
Statement of Need/Program Overview
The goal of this program is to provide important clinical data on the management of HBV.
 
Educational Objectives
Upon completion of this activity, participants should be better able to:
Present new data on the prevention of HBV recurrence after liver transplant, the efficacy of tenofovir after suboptimal response to adefovir, the influence of prior exposure to nucelos(t)ide analogues on the antiviral effect of entecavir, the impact on histology in Asian patients treated long term with entecavir, and combination treatment with entecavir and tenofovir.
 
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and Focus Medical Communications. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
 
Credit Designation
Purdue University College of Pharmacy designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.
 
Faculty Disclosure Statement
All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Dr. Schiff has received grants/research support from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Coley, Conatus, Daiichi-Sankyo, Debio Pharmaceuticals, Gilead, GlobeImmune, Idenix, LABCORE, Merck, Novartis/Idenix, Pfizer, Phynova, Roche, Salix, Sanofi-Aventis, Schering-Plough, Vertex and Valeant. He has served as a consultant for Dynavax Technologies and has served on the speakers bureau for Gilead and Schering-Plough. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. The Focus Medical Communications staff and Purdue University College of Pharmacy staff have no relationships to disclose.
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.